Literature DB >> 22430190

Poly thymidine polymorphism and cystic fibrosis in a non-Caucasian population.

Reza Tabaripour1, Haleh Akhavan Niaki, Mohammad Reza Esmaeeli Douki, Javad Tavakkoly Bazzaz, Bagher Larijani, Parichehr Yaghmaei.   

Abstract

BACKGROUND: Cystic fibrosis is a monogenic recessive disorder found predominantly in Caucasian population. This disease arises from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. In this study we consider poly T polymorphism c.1210-12T[5], c.1210-12T[7], c.1210-12T[9] (T{5}, T{7}, T{9}) in the intron 8 of CFTR gene in normal individuals and cystic fibrosis patients in the north of Iran.
MATERIAL AND METHODS: 40 CF patients and 40 normal individuals were screened for poly T polymorphism in intron 8 of CFTR gene using Reverse Dot Blot method which was also used to detect p.Phe508del among CF patients.
RESULTS: T{7} allele is the most prevalent in both normal and CF patients. Its abundance is approximately 75%. T{9} and T{5} represent approximately 20% and 5% of alleles respectively. T{7}/T{7} genotype is the most present in both normal and CF patients with 72.5% and 60% prevalence respectively. p.Phe508del was present in 13 CFTR alleles belonging to 7 patients with either homozygote T{9}/ T{9}, T{7}/ T{7} or compound heterozygote T{7}/ T{9} genotypes.
CONCLUSION: Contrary to the Caucasians, T{7} allele is more frequent in Northern Iranian CF patients. The presence of p.Phe508del and T{7} allele in the same framework is reported for the first time in this part of the world. Further investigations of other populations will help to understand whether p.Phe508del arose by selection pressure in this part of the world or was imported from European countries. The abundance of T{5}, T{7}, T{9} alleles indicates that this polymorphism can be used as one of the informative markers for detection of normal and mutant alleles in prenatal diagnosis or carrier assessment in families with previous history of the disease in regions with high degree of CFTR mutation heterogeneity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22430190      PMCID: PMC3826484          DOI: 10.3233/DMA-2011-0880

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  3 in total

1.  Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.

Authors:  Richard B Moss; Patrick A Flume; J Stuart Elborn; Jon Cooke; Steven M Rowe; Susanna A McColley; Ronald C Rubenstein; Mark Higgins
Journal:  Lancet Respir Med       Date:  2015-06-09       Impact factor: 30.700

2.  Differences in gene mutations between Chinese and Caucasian cystic fibrosis patients.

Authors:  Baoying Zheng; Ling Cao
Journal:  Pediatr Pulmonol       Date:  2016-10-07

3.  c.753_754delAG, a novel CFTR mutation found in a Chinese patient with cystic fibrosis: A case report and review of the literature.

Authors:  Yu-Qing Wang; Chuang-Li Hao; Wu-Jun Jiang; Yan-Hong Lu; Hui-Quan Sun; Chun-Yan Gao; Min Wu
Journal:  World J Clin Cases       Date:  2019-08-06       Impact factor: 1.337

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.